385 related articles for article (PubMed ID: 34638388)
1. Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies.
Hussain K; Cragg MS; Beers SA
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638388
[TBL] [Abstract][Full Text] [Related]
2. HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Hussain K; Liu R; Smith RCG; Müller KTJ; Ghorbani M; Macari S; Cleary KLS; Oldham RJ; Foxall RB; James S; Booth SG; Murray T; Dahal LN; Hargreaves CE; Kemp RS; Longley J; Douglas J; Markham H; Chee SJ; Stopforth RJ; Roghanian A; Carter MJ; Ottensmeier CH; Frendéus B; Cutress RI; French RR; Glennie MJ; Strefford JC; Thirdborough SM; Beers SA; Cragg MS
J Exp Clin Cancer Res; 2022 Apr; 41(1):131. PubMed ID: 35392965
[TBL] [Abstract][Full Text] [Related]
3. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
[TBL] [Abstract][Full Text] [Related]
4. Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes.
Li H; Somiya M; Kuroda S
Biomaterials; 2021 Jan; 268():120601. PubMed ID: 33338932
[TBL] [Abstract][Full Text] [Related]
5. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
6. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
[TBL] [Abstract][Full Text] [Related]
7. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis.
Kern N; Dong R; Douglas SM; Vale RD; Morrissey MA
Elife; 2021 Jun; 10():. PubMed ID: 34080973
[TBL] [Abstract][Full Text] [Related]
8. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
9. Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.
Pinney JJ; Rivera-Escalera F; Chu CC; Whitehead HE; VanDerMeid KR; Nelson AM; Barbeau MC; Zent CS; Elliott MR
Blood; 2020 Oct; 136(18):2065-2079. PubMed ID: 32556153
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Laengle J; Kabiljo J; Hunter L; Homola J; Prodinger S; Egger G; Bergmann M
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940587
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor-associated macrophages for cancer immunotherapy.
Cao X; Lai SWT; Chen S; Wang S; Feng M
Int Rev Cell Mol Biol; 2022; 368():61-108. PubMed ID: 35636930
[TBL] [Abstract][Full Text] [Related]
12. Method for Measurement of Antibody-Dependent Cellular Phagocytosis.
Kamen L; Ordonia B; Myneni S; Chung S
Methods Mol Biol; 2022; 2313():305-312. PubMed ID: 34478147
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
[TBL] [Abstract][Full Text] [Related]
14. Macrophages are critical effectors of antibody therapies for cancer.
Weiskopf K; Weissman IL
MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
[TBL] [Abstract][Full Text] [Related]
15. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
16. A novel method for determining antibody-dependent cellular phagocytosis.
Kamen L; Myneni S; Langsdorf C; Kho E; Ordonia B; Thakurta T; Zheng K; Song A; Chung S
J Immunol Methods; 2019 May; 468():55-60. PubMed ID: 30880262
[TBL] [Abstract][Full Text] [Related]
17. Protocol for the murine antibody-dependent cellular phagocytosis assay.
Stanganello E; Brkic M; Zenner S; Beulshausen I; Schmitt U; Vascotto F
Methods Cell Biol; 2023; 173():109-120. PubMed ID: 36653078
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
19. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
[TBL] [Abstract][Full Text] [Related]
20. Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Musolino A; Gradishar WJ; Rugo HS; Nordstrom JL; Rock EP; Arnaldez F; Pegram MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
